Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

22 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Telavancin for Injection Articles

Clinigen and Theravance deal on Vibativ; Cubist expands rights to ceftolozane

12 March 2013

Mixed FDA panel vote for Theravance's Vibativ for nosocomial pneumonia

3 December 2012

Astellas pulls out of deal with Theravance

9 January 2012

Astellas get EU approval for Vibativ for nosocomial pneumonia caused by MRSA

15 September 2011

Majority of US surveyed MCOs will consider reimbursing novel OPAT agents; report

17 August 2011

Slew of good news from EMA advisory panel for Benlysta, Fampyra, Vibativ, Victrelis, Xgeva and Yervoy

23 May 2011

Generic erosion will constrain hospital-acquired infections drug market growth through 2019

14 December 2010

US FDA says Theravance/Astellas’ Vibativ NDA for NP is incomplete

29 January 2010

Health Canada clears Astellas/Theravance’s Vibativ for cSSSI indications

2 October 2009

US FDA approves Theravance and Astellas’ Vibativ

14 September 2009

CHMP gives nod to Vidaza and Lunivia, while Astellas withdraws telavancin MAA

3 November 2008

Showing 1-11 of 11 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Is failure to adopt business process management putting the pharma industry at risk?
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
  • Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
  • Boehringer Ingelheim gets FDA warning letter on cGMP failures
  • Is failure to adopt business process management putting the pharma industry at risk?
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
  • Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
  • Boehringer Ingelheim gets FDA warning letter on cGMP failures

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS